The Fort Worth Press - enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

USD -
AED 3.67298
AFN 69.911879
ALL 88.480839
AMD 387.867986
ANG 1.790204
AOA 916.502891
ARS 1130.479705
AUD 1.560645
AWG 1.8025
AZN 1.699692
BAM 1.760475
BBD 2.01821
BDT 121.44561
BGN 1.76115
BHD 0.376908
BIF 2973.954606
BMD 1
BND 1.304667
BOB 6.906795
BRL 5.669757
BSD 0.999608
BTN 85.262414
BWP 13.645733
BYN 3.271208
BYR 19600
BZD 2.00784
CAD 1.39947
CDF 2870.00025
CHF 0.84212
CLF 0.02462
CLP 944.770206
CNY 7.2033
CNH 7.199895
COP 4225.76
CRC 507.95051
CUC 1
CUP 26.5
CVE 99.254232
CZK 22.454021
DJF 177.997606
DKK 6.71438
DOP 58.725308
DZD 133.799008
EGP 50.460157
ERN 15
ETB 132.91142
EUR 0.90011
FJD 2.27435
FKP 0.758117
GBP 0.75659
GEL 2.744979
GGP 0.758117
GHS 12.97501
GIP 0.758117
GMD 72.185616
GNF 8644.084937
GTQ 7.676855
GYD 208.831209
HKD 7.795191
HNL 25.850215
HRK 6.783602
HTG 130.551477
HUF 364.460852
IDR 16652.234449
ILS 3.576775
IMP 0.758117
INR 85.311651
IQD 1308.750205
IRR 42250.000055
ISK 132.089855
JEP 0.758117
JMD 158.647385
JOD 0.709296
JPY 148.132032
KES 129.273661
KGS 87.449869
KHR 4005.603722
KMF 432.742967
KPW 899.995499
KRW 1424.178899
KWD 0.307561
KYD 0.831723
KZT 510.584696
LAK 21579.899499
LBP 89417.197299
LKR 298.308077
LRD 199.620755
LSL 18.294547
LTL 2.95274
LVL 0.60489
LYD 5.469605
MAD 9.335974
MDL 17.233399
MGA 4478.082969
MKD 55.383519
MMK 2099.484484
MNT 3573.897983
MOP 8.011224
MRU 39.603061
MUR 46.200002
MVR 15.4386
MWK 1730.811193
MXN 19.57697
MYR 4.338498
MZN 63.830001
NAD 18.295948
NGN 1601.759833
NIO 36.742251
NOK 10.41485
NPR 135.656652
NZD 1.697145
OMR 0.384977
PAB 1
PEN 3.646011
PGK 4.106745
PHP 55.812007
PKR 280.971339
PLN 3.826801
PYG 7974.852027
QAR 3.641932
RON 4.595098
RSD 105.588895
RUB 80.500757
RWF 1428.782309
SAR 3.750748
SBD 8.350849
SCR 14.211704
SDG 600.469215
SEK 9.741895
SGD 1.305194
SHP 0.785843
SLE 22.75048
SLL 20969.48728
SOS 570.419531
SRD 36.199503
STD 20697.981008
SVC 8.733172
SYP 13003.313899
SZL 18.292705
THB 33.258002
TJS 10.400007
TMT 3.5
TND 3.037043
TOP 2.40776
TRY 38.77753
TTD 6.77531
TWD 30.47175
TZS 2696.000211
UAH 41.462524
UGX 3652.679524
UYU 41.777225
UZS 12885.066485
VES 92.714987
VND 25957
VUV 119.97318
WST 2.778545
XAF 590.662242
XAG 0.030501
XAU 0.000308
XCD 2.700001
XDR 0.720178
XOF 590.662242
XPF 107.453315
YER 244.710951
ZAR 18.38368
ZMK 9001.202465
ZMW 26.279733
ZWL 321.999592
  • RBGPF

    2.2700

    65.27

    +3.48%

  • CMSC

    0.0200

    22.08

    +0.09%

  • RYCEF

    -0.1200

    10.38

    -1.16%

  • RIO

    1.4300

    61.41

    +2.33%

  • BCC

    4.4800

    93.1

    +4.81%

  • RELX

    -2.0200

    51.83

    -3.9%

  • CMSD

    -0.0400

    22.3

    -0.18%

  • SCS

    0.3600

    10.82

    +3.33%

  • NGG

    -3.1600

    67.53

    -4.68%

  • GSK

    0.7500

    37.37

    +2.01%

  • BCE

    -0.1500

    22.56

    -0.66%

  • VOD

    -0.2300

    9.07

    -2.54%

  • BTI

    -0.6600

    40.98

    -1.61%

  • JRI

    0.0300

    13.01

    +0.23%

  • AZN

    1.3800

    68.95

    +2%

  • BP

    0.4200

    30.19

    +1.39%

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Text size:

IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it participated in the Virtual Investor "Top 5 for '25" On-Demand Conference. 

As part of the event, Robert Berman, Chief Executive Officer of enVVeno, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025. 

The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the Company's website (envveno.com).

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

###

INVESTOR CONTACT:

Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775

SOURCE: enVVeno Medical Corporation



View the original press release on ACCESS Newswire

T.Dixon--TFWP